NL301209I2 - capmatinib of een farmaceutisch aanvaardbaar zout daarvan - Google Patents

capmatinib of een farmaceutisch aanvaardbaar zout daarvan

Info

Publication number: NL301209I2
Authority: NL; Netherlands
Prior art keywords: capmatinib; pharmaceutically acceptable; acceptable salt; salt; pharmaceutically
Prior art date: 2006-11-22

Application number

NL301209C

Other languages

English (en)

Other versions

NL301209I1 (nl

Original Assignee

Incyte Holdings Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-11-22

Filing date

2022-12-16

Publication date

2023-01-24

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39166437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL301209(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2022-12-16 Application filed by Incyte Holdings Corp filed Critical Incyte Holdings Corp

2022-12-21 Publication of NL301209I1 publication Critical patent/NL301209I1/nl

2023-01-24 Publication of NL301209I2 publication Critical patent/NL301209I2/nl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Oncology (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Transplantation (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Biomedical Technology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Gastroenterology & Hepatology (AREA)
Neurology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Cosmetics (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NL301209C 2006-11-22 2022-12-16 capmatinib of een farmaceutisch aanvaardbaar zout daarvan NL301209I2 (nl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US86084006P	2006-11-22	2006-11-22
US86145906P	2006-11-29	2006-11-29
US95723607P	2007-08-22	2007-08-22
PCT/US2007/085100 WO2008064157A1 (en)	2006-11-22	2007-11-19	Imidazotriazines and imidazopyrimidines as kinase inhibitors

Publications (2)

Publication Number	Publication Date
NL301209I1 NL301209I1 (nl)	2022-12-21
NL301209I2 true NL301209I2 (nl)	2023-01-24

Family

ID=39166437

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL301209C NL301209I2 (nl)	2006-11-22	2022-12-16	capmatinib of een farmaceutisch aanvaardbaar zout daarvan

Country Status (37)

Country	Link
US (7)	US7767675B2 (nl)
EP (4)	EP3443958A1 (nl)
JP (1)	JP5572388B2 (nl)
KR (2)	KR101588583B1 (nl)
CN (2)	CN103288833B (nl)
AR (1)	AR066142A1 (nl)
AU (1)	AU2007323725B2 (nl)
BR (1)	BRPI0719333A2 (nl)
CA (1)	CA2669991C (nl)
CL (1)	CL2007003341A1 (nl)
CO (1)	CO6210810A2 (nl)
CR (1)	CR10841A (nl)
CY (4)	CY1116763T1 (nl)
DK (3)	DK2099447T3 (nl)
EA (2)	EA032254B1 (nl)
EC (1)	ECSP099400A (nl)
ES (3)	ES2689444T3 (nl)
FR (1)	FR22C1060I2 (nl)
GE (1)	GEP20125658B (nl)
HK (3)	HK1136489A1 (nl)
HR (3)	HRP20130106T1 (nl)
HU (2)	HUE026659T2 (nl)
IL (4)	IL198716A (nl)
LT (1)	LT3034075T (nl)
LU (1)	LUC00293I2 (nl)
ME (2)	ME01507B (nl)
MX (1)	MX2009005144A (nl)
MY (2)	MY188335A (nl)
NL (1)	NL301209I2 (nl)
NO (4)	NO346024B1 (nl)
NZ (1)	NZ577127A (nl)
PL (3)	PL3034075T3 (nl)
PT (3)	PT2099447E (nl)
RS (3)	RS52677B (nl)
SI (3)	SI2497470T1 (nl)
TW (1)	TWI429432B (nl)
WO (1)	WO2008064157A1 (nl)

Families Citing this family (143)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI2455382T1 (sl)	2005-12-13	2017-03-31	Incyte Holdings Corporation	S heteroarilom substituirani pirolo(2,3b)piridini in pirolo(2,3-b)pirimidini kot zaviralci janus kinaze
DK2010493T3 (en) *	2006-04-12	2016-05-02	Merck Sharp & Dohme	PYRIDYLAMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS
CA2660836A1 (en) *	2006-08-07	2008-02-21	Incyte Corporation	Triazolotriazines as kinase inhibitors
RS52677B (en)	2006-11-22	2013-06-28	Incyte Corporation	IMIDAZOTRIAZINI I IMIDAZOPIRIMIDINI KAO INHIBITORI KINAZE
MY154969A (en)	2007-06-13	2015-08-28	Incyte Corp	Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
AU2008317353B2 (en) *	2007-10-24	2014-08-07	Merck Sharp & Dohme Llc	Heterocycle phenyl amide T-type calcium channel antagonists
EA201001365A1 (ru)	2008-02-28	2011-04-29	Новартис Аг	ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОПОСРЕДУЕМОГО C-МЕТ ТИРОЗИНКИНАЗОЙ
BRPI0912882A2 (pt) *	2008-05-21	2017-05-16	Incyte Corp	sais de 2-flúor-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida e processos relacionados à preparação dos mesmos
WO2010002472A1 (en) *	2008-07-02	2010-01-07	Ambit Biosciences Corporation	Jak kinase modulating compounds and methods of use thereof
FR2933982A1 (fr) *	2008-07-18	2010-01-22	Sanofi Aventis	Nouveaux derives imidazo°1,2-a!pyrimidine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
UY32049A (es) *	2008-08-14	2010-03-26	Takeda Pharmaceutical	Inhibidores de cmet
JOP20190230A1 (ar)	2009-01-15	2017-06-16	Incyte Corp	طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
JP5777526B2 (ja) *	2009-02-13	2015-09-09	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	縮合ピリミジン類
JP5775070B2 (ja)	2009-05-22	2015-09-09	インサイト・コーポレイションＩｎｃｙｔｅＣｏｒｐｏｒａｔｉｏｎ	ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体
NZ596374A (en)	2009-05-22	2014-01-31	Incyte Corp	3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
AR077280A1 (es)	2009-06-29	2011-08-17	Incyte Corp	Pirimidinonas como inhibidores de pi3k, y composiciones farmaceuticas que los comprenden
JP5781510B2 (ja)	2009-08-12	2015-09-24	ノバルティスアーゲー	ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
IN2012DN01453A (nl) *	2009-08-20	2015-06-05	Novartis Ag
WO2011028685A1 (en)	2009-09-01	2011-03-10	Incyte Corporation	Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
US8759359B2 (en)	2009-12-18	2014-06-24	Incyte Corporation	Substituted heteroaryl fused derivatives as PI3K inhibitors
ME02211B (me)	2009-12-31	2016-02-20	Hutchison Medipharma Ltd	Neki triazolopirazini, njihove kompozicije i postupci njihovog korišćenja
EA025304B1 (ru)	2010-02-03	2016-12-30	Инсайт Холдингс Корпорейшн	ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ
SMT202000373T1 (it)	2010-03-10	2020-09-10	Incyte Holdings Corp	Piperidin-4-il azetidin derivati come inibitori di jak1
US8518945B2 (en) *	2010-03-22	2013-08-27	Hoffmann-La Roche Inc.	Pyrrolopyrazine kinase inhibitors
US8410117B2 (en) *	2010-03-26	2013-04-02	Hoffmann-La Roche Inc.	Imidazopyrimidine derivatives
EP2558463A1 (en)	2010-04-14	2013-02-20	Incyte Corporation	Fused derivatives as i3 inhibitors
US8962596B2 (en) *	2010-04-14	2015-02-24	Array Biopharma Inc.	5,7-substituted-imidazo[1,2-C]pyrimidines as inhibitors of JAK kinases
ES2715611T3 (es)	2010-05-17	2019-06-05	Incozen Therapeutics Pvt Ltd	Compuestos novedosos de 3H-imidazo[4,5-b]piridina-3,5-disustituida y 3H-[1,2,3]triazolo[4,5-b]piridina 3,5-disustituida como moduladores de proteína cinasas
SG10201910912TA (en)	2010-05-21	2020-01-30	Incyte Corp	Topical Formulation for a JAK Inhibitor
WO2012068440A1 (en)	2010-11-19	2012-05-24	Incyte Corporation	Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
EA026201B1 (ru)	2010-11-19	2017-03-31	Инсайт Холдингс Корпорейшн	Циклобутилзамещенные производные пирролопиридина и пирролопиримидина как ингибиторы jak
EP2655374B1 (en)	2010-12-20	2019-10-23	Incyte Holdings Corporation	N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
WO2012105594A1 (ja)	2011-02-01	2012-08-09	協和発酵キリン株式会社	縮環複素環誘導体
WO2012125629A1 (en)	2011-03-14	2012-09-20	Incyte Corporation	Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
WO2012135009A1 (en)	2011-03-25	2012-10-04	Incyte Corporation	Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
BR112013032720A2 (pt)	2011-06-20	2016-09-13	Incyte Corp	"derivados de azetidinil fenil, piridil ou pirazinil carboxamida como inibidores de jak, composição e uso dos referidos derivados"
TW201313721A (zh)	2011-08-18	2013-04-01	Incyte Corp	作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UY34305A (es)	2011-09-01	2013-04-30	Novartis Ag	Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
SMT202100288T1 (it)	2011-09-02	2021-07-12	Incyte Holdings Corp	Eterociclilammine come inibitori di pi3k
UA111854C2 (uk)	2011-09-07	2016-06-24	Інсайт Холдінгс Корпорейшн	Способи і проміжні сполуки для отримання інгібіторів jak
ES2691650T3 (es)	2011-09-15	2018-11-28	Novartis Ag	3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como inhibidores de tirosina quinasa c-Met
CN103030654A (zh) *	2011-10-09	2013-04-10	济南赛文医药技术有限公司	一种小分子c-Met蛋白激酶抑制剂
CN103987713A (zh) *	2011-10-12	2014-08-13	阵列生物制药公司	5,7-取代的咪唑并[1,2-c]嘧啶
EP3750544B1 (en)	2011-11-30	2025-03-05	Emory University	Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
AR090548A1 (es)	2012-04-02	2014-11-19	Incyte Corp	Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
CN104244982A (zh)	2012-04-03	2014-12-24	诺华股份有限公司	酪氨酸激酶抑制剂组合及其用途
CN104245701A (zh)	2012-04-03	2014-12-24	诺华有限公司	有酪氨酸激酶抑制剂的组合产品和其应用
WO2013173720A1 (en)	2012-05-18	2013-11-21	Incyte Corporation	Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
ME03300B (me)	2012-06-13	2019-07-20	Incyte Holdings Corp	Supsтituisana triciklična jedinjenja као inhibiтori fgfr
WO2014028566A1 (en) *	2012-08-16	2014-02-20	Novartis Ag	Combination of pi3k inhibitor and c-met inhibitor
IL291391B (en)	2012-11-15	2022-11-01	Incyte Holdings Corp	Sustained-release dosage forms of ruxolitinib
US9073921B2 (en)	2013-03-01	2015-07-07	Novartis Ag	Salt forms of bicyclic heterocyclic derivatives
EA201891157A1 (ru)	2013-03-06	2019-02-28	Инсайт Холдингс Корпорейшн	Способы и промежуточные соединения при получении ингибитора jak
CN107312009B (zh) *	2013-04-17	2022-09-20	上海医药集团股份有限公司	喹啉类化合物、其制备方法、中间体、药物组合物和应用
WO2014174478A1 (en)	2013-04-26	2014-10-30	Novartis Ag	Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
SG10201801069QA (en)	2013-08-07	2018-03-28	Incyte Corp	Sustained release dosage forms for a jak1 inhibitor
US10570204B2 (en)	2013-09-26	2020-02-25	The Medical College Of Wisconsin, Inc.	Methods for treating hematologic cancers
GB201321732D0 (en) *	2013-12-09	2014-01-22	Ucb Pharma Sa	Therapeutic agents
GB201321736D0 (en) *	2013-12-09	2014-01-22	Ucb Pharma Sa	Therapeutic agents
JOP20200094A1 (ar)	2014-01-24	2017-06-16	Dana Farber Cancer Inst Inc	جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar)	2014-01-31	2017-06-16	Children’S Medical Center Corp	جزيئات جسم مضاد لـ tim-3 واستخداماتها
US9527835B2 (en)	2014-02-13	2016-12-27	Incyte Corporation	Cyclopropylamines as LSD1 inhibitors
WO2015123408A1 (en)	2014-02-13	2015-08-20	Incyte Corporation	Cyclopropylamines as lsd1 inhibitors
CN111454188A (zh)	2014-02-13	2020-07-28	因赛特公司	作为lsd1抑制剂的环丙胺
EA201691594A1 (ru)	2014-02-13	2017-02-28	Инсайт Корпорейшн	Циклопропиламины в качестве ингибиторов lsd1
ME03558B (me)	2014-03-14	2020-07-20	Novartis Ag	Molekuli anti-lag-3 antiтela i njihove upotrebe
JP6752715B2 (ja)	2014-03-26	2020-09-09	アステックス、セラピューティックス、リミテッドＡｓｔｅｘＴｈｅｒａｐｅｕｔｉｃｓＬｉｍｉｔｅｄ	組合せ
US9498467B2 (en)	2014-05-30	2016-11-22	Incyte Corporation	Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US10077277B2 (en)	2014-06-11	2018-09-18	Incyte Corporation	Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
WO2016007727A1 (en)	2014-07-10	2016-01-14	Incyte Corporation	Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9695168B2 (en)	2014-07-10	2017-07-04	Incyte Corporation	Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
WO2016007722A1 (en)	2014-07-10	2016-01-14	Incyte Corporation	Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007736A1 (en)	2014-07-10	2016-01-14	Incyte Corporation	Imidazopyrazines as lsd1 inhibitors
EA202191301A1 (ru) *	2014-07-25	2021-11-30	Новартис Аг	СОСТАВ ТАБЛЕТОК 2-ФТОР-N-МЕТИЛ-4-[7-(ХИНОЛИН-6-ИЛМЕТИЛ)ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИН-2-ИЛ]БЕНЗАМИДА
WO2016011658A1 (en) *	2014-07-25	2016-01-28	Novartis Ag	Combination therapy
MX2017001461A (es)	2014-07-31	2017-05-11	Novartis Ag	Terapia de combinacion.
CN107206071A (zh)	2014-09-13	2017-09-26	诺华股份有限公司	Alk抑制剂的联合疗法
EP3200775B1 (en)	2014-10-03	2019-11-20	Novartis AG	Combination therapies
MA41044A (fr)	2014-10-08	2017-08-15	Novartis Ag	Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
UY36351A (es)	2014-10-14	2016-06-01	Novartis Ag	Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
UA121669C2 (uk) *	2015-02-20	2020-07-10	Інсайт Корпорейшн	Біциклічні гетероцикли як інгібітори fgfr
TWI713497B (zh) *	2015-02-26	2020-12-21	南韓商愛思開生物製藥股份有限公司	咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物
KR20240132104A (ko)	2015-02-27	2024-09-02	인사이트 홀딩스 코포레이션	Pi3k 억제제의 염 및 이의 제조 공정
JO3746B1 (ar)	2015-03-10	2021-01-31	Aduro Biotech Inc	تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
AU2016243939B2 (en)	2015-04-03	2020-09-03	Incyte Holdings Corporation	Heterocyclic compounds as LSD1 inhibitors
CN106715440B (zh)	2015-04-21	2019-02-22	江苏恒瑞医药股份有限公司	咪唑并异吲哚类衍生物、其制备方法及其在医药上的应用
WO2016183063A1 (en)	2015-05-11	2016-11-17	Incyte Corporation	Crystalline forms of a pi3k inhibitor
WO2016183060A1 (en)	2015-05-11	2016-11-17	Incyte Corporation	Process for the synthesis of a phosphoinositide 3-kinase inhibitor
RU2683022C1 (ru)	2015-05-22	2019-03-26	Чонг Кун Данг Фармасьютикал Корп.	Производные гетероциклические алкильные соединения в качестве селективных ингибиторов гистондеацетилазы и содержащие их фармацевтические композиции
EP3317301B1 (en)	2015-07-29	2021-04-07	Novartis AG	Combination therapies comprising antibody molecules to lag-3
EP3316902A1 (en)	2015-07-29	2018-05-09	Novartis AG	Combination therapies comprising antibody molecules to tim-3
US20180222982A1 (en)	2015-07-29	2018-08-09	Novartis Ag	Combination therapies comprising antibody molecules to pd-1
EP3334709B1 (en)	2015-08-12	2024-12-11	Incyte Holdings Corporation	Salts of an lsd1 inhibitor
AU2016369623A1 (en) *	2015-12-17	2018-06-28	Novartis Ag	Combination of c-Met inhibitor with antibody molecule to PD-1 and uses thereof
US20180371093A1 (en)	2015-12-17	2018-12-27	Novartis Ag	Antibody molecules to pd-1 and uses thereof
UA125463C2 (uk)	2016-01-27	2022-03-16	Універсітет Цюріх	ЗАСТОСУВАННЯ МОДУЛЯТОРІВ GABA<sub>A</sub>-РЕЦЕПТОРА ДЛЯ ЛІКУВАННЯ СВЕРБЕЖУ
CR20180516A (es) *	2016-03-28	2019-03-05	Incyte Corp	Compuestos de iprrolotriazina como inhibidores de tam
AR109452A1 (es)	2016-04-22	2018-12-12	Incyte Corp	Formulación farmacéutica de un inhibidor de lsd1 y método de tratamiento
JP7027343B2 (ja) *	2016-05-23	2022-03-01	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｄｋ８／ｃｄｋ１９阻害剤としての新しいフェニルピラゾリルアセトアミド化合物及び誘導体
US11098077B2 (en)	2016-07-05	2021-08-24	Chinook Therapeutics, Inc.	Locked nucleic acid cyclic dinucleotide compounds and uses thereof
CN106496000A (zh) *	2016-10-19	2017-03-15	蚌埠学院	一种3‑氟‑4‑溴‑苯乙酮的合成方法
US10287303B2 (en)	2016-12-22	2019-05-14	Calithera Biosciences, Inc.	Compositions and methods for inhibiting arginase activity
UY37695A (es)	2017-04-28	2018-11-30	Novartis Ag	Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CU24606B1 (es)	2017-06-22	2022-06-06	Novartis Ag	Moléculas de anticuerpo que se unen a cd73
US20200172628A1 (en)	2017-06-22	2020-06-04	Novartis Ag	Antibody molecules to cd73 and uses thereof
CN111386273B (zh)	2017-09-27	2024-06-14	因赛特公司	可用作tam抑制剂的吡咯并三嗪衍生物的盐
KR102740831B1 (ko)	2017-11-14	2024-12-11	칠드런'즈 메디컬 센터 코포레이션	신규 이미다조피리미딘 화합물 및 그의 용도
JP7382316B2 (ja) *	2017-11-14	2023-11-16	ザチルドレンズメディカルセンターコーポレーション	ヒト免疫応答をモジュレートするためのイミダゾピリミジンの使用
TW201922291A (zh)	2017-11-16	2019-06-16	瑞士商諾華公司	組合療法
AR113922A1 (es)	2017-12-08	2020-07-01	Incyte Corp	Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
HRP20220510T1 (hr)	2018-01-30	2022-05-27	Incyte Corporation	Postupci za pripravu (1-(3-fluoro-2-(trifluorometil)izonikotinil) piperidin-4-ona)
EP4424328A3 (en)	2018-03-30	2024-12-04	Incyte Corporation	Treatment of hidradenitis suppurativa using jak inhibitors
MX2020011639A (es)	2018-05-04	2021-02-15	Incyte Corp	Sales de un inhibidor de receptores de factor de crecimiento de fibroblastos (fgfr).
CN110526916B (zh) *	2018-05-23	2021-07-13	海创药业股份有限公司	氘代Capmatinib化合物及其用途
AR126019A1 (es)	2018-05-30	2023-09-06	Novartis Ag	Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
WO2019232244A2 (en)	2018-05-31	2019-12-05	Novartis Ag	Antibody molecules to cd73 and uses thereof
SG11202011680YA (en)	2018-06-01	2020-12-30	Incyte Corp	Dosing regimen for the treatment of pi3k related disorders
CN108530337B (zh) *	2018-06-25	2020-11-03	南华大学	一种可选择性抑制胃癌细胞的吲哚酰胺类化合物
AR116109A1 (es)	2018-07-10	2021-03-31	Novartis Ag	Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
US10968200B2 (en)	2018-08-31	2021-04-06	Incyte Corporation	Salts of an LSD1 inhibitor and processes for preparing the same
CA3118093A1 (en) *	2018-09-28	2020-04-02	Arizona Board Of Regents On Behalf Of The University Of Arizona	Small molecule inhibitors of dyrk1/clk and uses thereof
MX2021007392A (es)	2018-12-20	2021-08-24	Novartis Ag	Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
CR20210336A (es) *	2018-12-20	2021-12-06	Incyte Corp	Compuestos de imidazopiridazina e imidazopiridina como inhibidores de quinasa-2 de tipo receptor de activina
JPWO2020130125A1 (ja)	2018-12-21	2021-11-04	第一三共株式会社	抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
MX2021009763A (es)	2019-02-15	2021-09-08	Novartis Ag	Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
EA202192029A1 (ru)	2019-02-15	2021-10-27	Новартис Аг	Замещенные производные 3-(1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и варианты их применения
US20220348651A1 (en)	2019-09-18	2022-11-03	Novartis Ag	Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
CN115151539A (zh)	2019-12-04	2022-10-04	因赛特公司	Fgfr抑制剂的衍生物
CA3165399A1 (en)	2019-12-20	2021-06-24	Novartis Ag	Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
WO2021173476A1 (en) *	2020-02-24	2021-09-02	The Trustees Of Columbia University In The City Of New York	Compounds, pharmaceutical formulations, and methods for treatment of cancer
CN115697343A (zh)	2020-03-06	2023-02-03	因赛特公司	包含axl/mer和pd-1/pd-l1抑制剂的组合疗法
US11833155B2 (en)	2020-06-03	2023-12-05	Incyte Corporation	Combination therapy for treatment of myeloproliferative neoplasms
CN111825678A (zh) *	2020-06-05	2020-10-27	连庆泉	一种卡马替尼的制备方法
IL298262A (en)	2020-06-23	2023-01-01	Novartis Ag	Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2022007752A1 (zh) *	2020-07-06	2022-01-13	苏州晶云药物科技股份有限公司	苯甲酰胺类化合物及其二盐酸盐的新晶型及其制备方法
TW202304979A (zh)	2021-04-07	2023-02-01	瑞士商諾華公司	抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CA3215903A1 (en)	2021-04-12	2022-10-20	Incyte Corporation	Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
AR125874A1 (es)	2021-05-18	2023-08-23	Novartis Ag	Terapias de combinación
AU2022336415A1 (en)	2021-09-01	2024-01-04	Novartis Ag	Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
CN113896732B (zh) *	2021-10-13	2023-09-12	沈阳红旗制药有限公司	抗癌药物卡马替尼的制备方法及其应用
WO2023249994A1 (en) *	2022-06-22	2023-12-28	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
TW202421146A (zh)	2022-07-08	2024-06-01	瑞典商阿斯特捷利康公司	用於治療癌症的上皮生長因子受體酪胺酸激酶抑制劑與ｈｇｆ受體抑制劑的組合
CN116903627B (zh) *	2023-05-15	2024-01-16	云白药征武科技(上海)有限公司	一种咪唑并三嗪硫代苯甲酰胺衍生物及其制备方法和应用

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US1411859A (en)	1920-12-08	1922-04-04	Marchand Robert	Process for preparing hydrate of terpin
US2837520A (en) *	1955-05-26	1958-06-03	Ind Chimica Profarmaco S R L	Fluorescent materials on the basis of tetrazoindenes
US4209621A (en)	1979-04-27	1980-06-24	American Cyanamid Company	(Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines
US4405619A (en)	1981-09-02	1983-09-20	Diamond Shamrock Corporation	Antiinflammatory substituted-1,2,4-triazolo[4,3-b]-1,2,4-triazines
DE3311753A1 (de)	1983-03-31	1984-10-04	Hoechst Ag, 6230 Frankfurt	Substituierte 6-aryl-1,2,4-triazolo(4,3-b)pyridazine - ihre herstellung und verwendung -
JPS6337347A (ja)	1986-08-01	1988-02-18	Fuji Photo Film Co Ltd	直接ポジカラ−画像形成方法
JPS63199347A (ja)	1987-02-14	1988-08-17	Konica Corp	鮮鋭性の向上した高感度ハロゲン化銀写真感光材料
JPS63310891A (ja)	1987-06-12	1988-12-19	Yoshitomi Pharmaceut Ind Ltd	縮合ピリダジン化合物
US5236917A (en)	1989-05-04	1993-08-17	Sterling Winthrop Inc.	Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
JPH0313934A (ja)	1989-06-12	1991-01-22	Konica Corp	ハロゲン化銀写真感光材料
IL96432A0 (en)	1989-11-30	1991-08-16	Schering Ag	Pesticidal compositions containing pyridine derivatives and novel pyridine derivatives
JP2664264B2 (ja)	1990-02-15	1997-10-15	富士写真フイルム株式会社	ハロゲン化銀写真乳剤及びこれを用いた写真感光材料
FR2662163A1 (fr)	1990-05-16	1991-11-22	Lipha	Nouvelles 8-amino-1,2,4-triazolo(4,3-a) pyrazines, procedes de preparation et medicaments les contenant.
JPH04251243A (ja)	1991-01-09	1992-09-07	Konica Corp	ハロゲン化銀写真感光材料
FR2671551B1 (fr)	1991-01-15	1993-03-12	Adir	Nouveaux composes de structure aryl triazinique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5232618A (en)	1991-09-30	1993-08-03	E. I. Du Pont De Nemours And Company	Substantially constant boiling compositions of difluoromethane and trifluoroethane or perfluoroethane
JPH05232618A (ja)	1992-02-21	1993-09-10	Konica Corp	ハロゲン化銀写真感光材料
DE4309285A1 (de)	1993-03-23	1994-09-29	Boehringer Ingelheim Kg	Heterocyclen enthaltende Amidinderivate, ihre Herstellung und Verwendung
NZ502642A (en) *	1997-07-03	2002-06-28	Du Pont Pharm Co	Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
ES2137113B1 (es)	1997-07-29	2000-09-16	Almirall Prodesfarma Sa	Nuevos derivados de triazolo-piridazinas heterociclicos.
DE19734311A1 (de)	1997-08-08	1999-02-11	Bosch Gmbh Robert	Anordnung zur Übertragung optischer Signale mit Ersatzschaltungswirkung
JP4251243B2 (ja)	1998-11-26	2009-04-08	株式会社日立メディコ	領域拡張装置
JP4025468B2 (ja)	1999-07-29	2007-12-19	三井化学株式会社	有機電界発光素子
JP2003513977A (ja)	1999-11-10	2003-04-15	オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド	置換２−アリール−３−（ヘテロアリール）−イミダゾ［１，２−α］ピリミジン類および関連薬剤組成物および方法
CA2388593A1 (en)	1999-11-12	2001-05-17	Neurogen Corporation	Bicyclic and tricyclic heteroaromatic compounds
DE10010067A1 (de) *	2000-03-02	2001-09-06	Bayer Ag	Neue Imidazotriazinone und ihre Verwendung
AU2000240570A1 (en) *	2000-03-29	2001-10-08	Knoll Gesellschaft Mit Beschraenkter Haftung	Pyrrolopyrimidines as tyrosine kinase inhibitors
JP2001302667A (ja) *	2000-04-28	2001-10-31	Bayer Ag	イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
ES2251518T3 (es)	2000-11-10	2006-05-01	MERCK SHARP & DOHME LTD.	Derivados de imidazo-triazina como ligandos para receptores gaba.
GB0103926D0 (en) *	2001-02-17	2001-04-04	Astrazeneca Ab	Chemical compounds
EP1370559B1 (en)	2001-03-09	2006-04-19	Pfizer Products Inc.	Triazolopyridines as anti-inflammatory agents
GB0107751D0 (en)	2001-03-28	2001-05-16	Pfizer Ltd	Pharmaceutically active compounds
CA2448076A1 (en)	2001-05-24	2002-11-28	Masahiko Hayakawa	3-quinoline-2-(1h)-ylideneindolin-2-one derivatives
DE10130167A1 (de) *	2001-06-22	2003-01-02	Bayer Ag	Imidazotriazine
WO2003074525A1 (fr)	2002-03-01	2003-09-12	Yamanouchi Pharmaceutical Co., Ltd.	Compose heterocyclique azote
AU2003223295A1 (en)	2002-03-19	2003-10-08	Merck And Co., Inc.	Process and intermediates to substituted imidazopyrimidines
US6790852B2 (en)	2002-04-18	2004-09-14	Hoffmann-La Roche Inc.	2-(2,6-dichlorophenyl)-diarylimidazoles
GB0210127D0 (en)	2002-05-02	2002-06-12	Merck Sharp & Dohme	Therapeutic agents
GB0210124D0 (en)	2002-05-02	2002-06-12	Merck Sharp & Dohme	Therapeutic agents
GB0211649D0 (en)	2002-05-21	2002-07-03	Novartis Ag	Organic compounds
DE10230604A1 (de)	2002-07-08	2004-01-29	Bayer Ag	Heterocyclisch substituierte Imidazotriazine
DE10230605A1 (de)	2002-07-08	2004-01-29	Bayer Ag	Substituierte Imidazotriazine
AU2003253188A1 (en)	2002-08-30	2004-03-19	Pfizer Products Inc.	Novel processes and intermediates for preparing triazolo-pyridines
US6784297B2 (en)	2002-09-04	2004-08-31	Kopran Limited	Process for the preparation of anti-ischemic and anti-hypertensive drug amlodipine besylate
ATE473980T1 (de)	2002-12-18	2010-07-15	Vertex Pharma	Triazolopyridazine als proteinkinase-inhibitoren
UA80171C2 (en) *	2002-12-19	2007-08-27	Pfizer Prod Inc	Pyrrolopyrimidine derivatives
GB0303910D0 (en) *	2003-02-20	2003-03-26	Merck Sharp & Dohme	Therapeutic agents
AP2114A (en)	2003-02-26	2010-03-04	Sugen Inc	Aminoheteroaryl compounds as protein kinase inhibitors
PA8595001A1 (es)	2003-03-04	2004-09-28	Pfizer Prod Inc	Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
EP1640010A1 (en)	2003-07-01	2006-03-29	Astellas Pharma Inc.	Agent inducing increase in bone mass
CA2529622A1 (en)	2003-07-02	2005-01-20	Sugen, Inc.	Indolinone hydrazides as c-met inhibitors
JP2007516180A (ja)	2003-07-02	2007-06-21	スゲン，インコーポレイティド	ｃ−Ｍｅｔ阻害薬としてのアリールメチルトリアゾロおよびイミダゾピラジン類
US7122548B2 (en)	2003-07-02	2006-10-17	Sugen, Inc.	Triazolotriazine compounds and uses thereof
US7037909B2 (en)	2003-07-02	2006-05-02	Sugen, Inc.	Tetracyclic compounds as c-Met inhibitors
ATE380816T1 (de)	2003-07-30	2007-12-15	S A L V A T Lab Sa	Substituierte imidazopyrimidine zur prävention und behandlung von krebs
AR045595A1 (es)	2003-09-04	2005-11-02	Vertex Pharma	Composiciones utiles como inhibidores de proteinas quinasas
CA2539726A1 (en)	2003-09-24	2005-05-06	Vertex Pharmaceuticals Incorporated	4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase
WO2005030140A2 (en)	2003-09-26	2005-04-07	Exelixis, Inc.	C-met modulators and methods of use
US7144889B2 (en)	2003-10-16	2006-12-05	Hoffman-La Roche Inc.	Triarylimidazoles
US7169781B2 (en)	2003-10-17	2007-01-30	Hoffmann-La Roche Inc.	Imidazole derivatives and their use as pharmaceutical agents
US7419978B2 (en)	2003-10-22	2008-09-02	Bristol-Myers Squibb Company	Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
GB0325031D0 (en)	2003-10-27	2003-12-03	Novartis Ag	Organic compounds
WO2005070891A2 (en)	2004-01-23	2005-08-04	Amgen Inc	Compounds and methods of use
EP1711495A2 (en)	2004-01-23	2006-10-18	Amgen Inc.	Quinoline, quinazoline, pyridine and pyrimidine counds and their use in the treatment of inflammation, angiogenesis and cancer
EP1719756A4 (en)	2004-02-18	2007-09-26	Banyu Pharma Co Ltd	DERIVATIVE NITROGENOUS, CONDENSED HETEROAROMATIC RING
UA89493C2 (uk) *	2004-04-02	2010-02-10	Оси Фармасьютикалз, Инк.	6,6-біциклічні кільцеві заміщені гетеробіциклічні інгібітори протеїнкіназ
US20050277650A1 (en)	2004-04-20	2005-12-15	Sundaram Venkataraman	Process for preparing aripirazole hydrate
WO2005113494A2 (en)	2004-05-07	2005-12-01	Amgen Inc.	Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
WO2005121125A1 (en)	2004-06-09	2005-12-22	Pfizer Inc.	Ether-linked heteroaryl compounds
AU2005270068B2 (en)	2004-07-02	2012-04-19	Exelixis, Inc.	C-Met modulators and method of use
MY139689A (en) *	2004-07-20	2009-10-30	Osi Pharm Inc	Imidazotriazines as protein kinase inhibitors
MX2007001127A (es) *	2004-07-27	2007-07-11	Sgx Pharmaceuticals Inc	Moduladores de pirrolo-piridina cinasa.
RS51362B (en)	2004-08-26	2011-02-28	Pfizer Inc.	ENANTIOMERALLY PURE AMINOHETEROARYL UNITS AS PROTEIN KINASE INHIBITORS
AU2005295734A1 (en)	2004-10-15	2006-04-27	Biogen Idec Ma Inc.	Methods of treating vascular injuries
JP4935357B2 (ja) *	2004-11-08	2012-05-23	Ｍｓｄ株式会社	新規縮環イミダゾール誘導体
US7456289B2 (en)	2004-12-31	2008-11-25	National Health Research Institutes	Anti-tumor compounds
CN101137412B (zh)	2005-01-13	2012-11-07	布里斯托尔-迈尔斯·斯奎布公司	用作凝血因子XIa抑制剂的取代的二芳基化合物
WO2006124354A2 (en) *	2005-05-12	2006-11-23	Merck & Co., Inc.	Tyrosine kinase inhibitors
US20080214562A1 (en)	2005-07-11	2008-09-04	Kristjan Gudmundsson	Chemical Compounds
WO2007015866A2 (en) *	2005-07-20	2007-02-08	Kalypsys, Inc.	Inhibitors of p38 kinase and methods of treating inflammatory disorders
JP2009502734A (ja)	2005-07-29	2009-01-29	アステラス製薬株式会社	Ｌｃｋ阻害剤としての縮合複素環
WO2007025090A2 (en)	2005-08-25	2007-03-01	Kalypsys, Inc.	Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
WO2007064797A2 (en)	2005-11-30	2007-06-07	Vertex Pharmaceuticals Incorporated	Inhibitors of c-met and uses thereof
UA98297C2 (en)	2005-12-21	2012-05-10	Янссен Фармацевтика, Н.В.	Triazolopyridazines as tyrosine kinase modulators
ES2761180T3 (es)	2005-12-23	2020-05-19	Ariad Pharma Inc	Compuestos bicíclicos de heteroarilo
WO2007096764A2 (en)	2006-02-27	2007-08-30	Glenmark Pharmaceuticals S.A.	Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
US8217177B2 (en)	2006-07-14	2012-07-10	Amgen Inc.	Fused heterocyclic derivatives and methods of use
PE20080403A1 (es)	2006-07-14	2008-04-25	Amgen Inc	Derivados heterociclicos fusionados y metodos de uso
CA2660836A1 (en)	2006-08-07	2008-02-21	Incyte Corporation	Triazolotriazines as kinase inhibitors
EP2081937B1 (en)	2006-10-23	2012-09-12	SGX Pharmaceuticals, Inc.	Triazolopyridazine protein kinase modulators
SG176461A1 (en)	2006-11-06	2011-12-29	Supergen Inc	Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
RS52677B (en) *	2006-11-22	2013-06-28	Incyte Corporation	IMIDAZOTRIAZINI I IMIDAZOPIRIMIDINI KAO INHIBITORI KINAZE
EP2162132A4 (en)	2007-05-21	2013-01-16	Sgx Pharmaceuticals Inc	Heterocyclic kinase modulators
BRPI0912882A2 (pt)	2008-05-21	2017-05-16	Incyte Corp	sais de 2-flúor-n-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida e processos relacionados à preparação dos mesmos
EA025304B1 (ru)	2010-02-03	2016-12-30	Инсайт Холдингс Корпорейшн	ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ
CA2832994A1 (en)	2011-05-06	2012-11-15	Takasago International Corporation	Ruthenium-diamine complex and method for producing optically active compound

2007
- 2007-11-19 RS RS20130041A patent/RS52677B/en unknown
- 2007-11-19 MY MYPI20092064A patent/MY188335A/en unknown
- 2007-11-19 MX MX2009005144A patent/MX2009005144A/es active IP Right Grant
- 2007-11-19 HU HUE12158715A patent/HUE026659T2/en unknown
- 2007-11-19 RS RS20160017A patent/RS54510B1/en unknown
- 2007-11-19 PL PL15191241T patent/PL3034075T3/pl unknown
- 2007-11-19 KR KR1020147033803A patent/KR101588583B1/ko active IP Right Grant
- 2007-11-19 BR BRPI0719333-5A patent/BRPI0719333A2/pt not_active Application Discontinuation
- 2007-11-19 DK DK07864592.6T patent/DK2099447T3/da active
- 2007-11-19 RS RS20181200A patent/RS57741B1/sr unknown
- 2007-11-19 EP EP18182215.6A patent/EP3443958A1/en active Pending
- 2007-11-19 CN CN201310141352.4A patent/CN103288833B/zh active Active
- 2007-11-19 SI SI200731739T patent/SI2497470T1/sl unknown
- 2007-11-19 EP EP07864592A patent/EP2099447B1/en active Active
- 2007-11-19 DK DK15191241.7T patent/DK3034075T3/en active
- 2007-11-19 SI SI200731149T patent/SI2099447T1/sl unknown
- 2007-11-19 PT PT78645926T patent/PT2099447E/pt unknown
- 2007-11-19 CN CN2007800503102A patent/CN101641093B/zh active Active
- 2007-11-19 DK DK12158715.8T patent/DK2497470T3/en active
- 2007-11-19 CA CA2669991A patent/CA2669991C/en active Active
- 2007-11-19 JP JP2009538473A patent/JP5572388B2/ja active Active
- 2007-11-19 NZ NZ577127A patent/NZ577127A/en unknown
- 2007-11-19 EA EA201691862A patent/EA032254B1/ru active IP Right Revival
- 2007-11-19 ES ES15191241.7T patent/ES2689444T3/es active Active
- 2007-11-19 ES ES12158715.8T patent/ES2560435T3/es active Active
- 2007-11-19 ME MEP-2013-35A patent/ME01507B/me unknown
- 2007-11-19 PT PT121587158T patent/PT2497470E/pt unknown
- 2007-11-19 EA EA200970501A patent/EA026126B1/ru unknown
- 2007-11-19 NO NO20200077A patent/NO346024B1/no unknown
- 2007-11-19 MY MYPI2013000862A patent/MY188338A/en unknown
- 2007-11-19 KR KR1020097013022A patent/KR101532256B1/ko active IP Right Grant
- 2007-11-19 ME MEP-2016-13A patent/ME02372B/me unknown
- 2007-11-19 PL PL12158715T patent/PL2497470T3/pl unknown
- 2007-11-19 EP EP12158715.8A patent/EP2497470B8/en active Active
- 2007-11-19 LT LTEP15191241.7T patent/LT3034075T/lt unknown
- 2007-11-19 EP EP15191241.7A patent/EP3034075B1/en active Active
- 2007-11-19 PL PL07864592T patent/PL2099447T3/pl unknown
- 2007-11-19 GE GEAP200711325A patent/GEP20125658B/en unknown
- 2007-11-19 ES ES07864592T patent/ES2398843T3/es active Active
- 2007-11-19 US US11/942,130 patent/US7767675B2/en active Active
- 2007-11-19 PT PT15191241T patent/PT3034075T/pt unknown
- 2007-11-19 WO PCT/US2007/085100 patent/WO2008064157A1/en active Application Filing
- 2007-11-19 AU AU2007323725A patent/AU2007323725B2/en active Active
- 2007-11-19 SI SI200732055T patent/SI3034075T1/sl unknown
- 2007-11-21 AR ARP070105176A patent/AR066142A1/es active IP Right Grant
- 2007-11-22 CL CL200703341A patent/CL2007003341A1/es unknown
- 2007-11-22 TW TW096144319A patent/TWI429432B/zh active
2009
- 2009-05-12 IL IL198716A patent/IL198716A/en active IP Right Grant
- 2009-05-18 NO NO20091924A patent/NO344399B1/no active Protection Beyond IP Right Term
- 2009-06-08 CR CR10841A patent/CR10841A/es unknown
- 2009-06-10 CO CO09060491A patent/CO6210810A2/es active IP Right Grant
- 2009-06-11 EC EC2009009400A patent/ECSP099400A/es unknown
2010
- 2010-02-25 HK HK10101978.2A patent/HK1136489A1/xx unknown
- 2010-02-25 HK HK13102854.6A patent/HK1175700A1/zh unknown
- 2010-06-10 US US12/813,148 patent/US8461330B2/en active Active
2013
- 2013-02-04 CY CY20131100098T patent/CY1116763T1/el unknown
- 2013-02-07 HR HRP20130106TT patent/HRP20130106T1/hr unknown
- 2013-05-16 US US13/895,799 patent/US20130324515A1/en not_active Abandoned
2016
- 2016-01-12 CY CY20161100026T patent/CY1117108T1/el unknown
- 2016-01-25 HR HRP20160077TT patent/HRP20160077T1/hr unknown
- 2016-02-05 US US15/016,841 patent/US9944645B2/en active Active
- 2016-02-23 IL IL244244A patent/IL244244B/en active IP Right Grant
- 2016-12-16 HK HK16114386A patent/HK1225978B/zh unknown
2018
- 2018-03-20 US US15/925,996 patent/US10738052B2/en active Active
- 2018-10-05 HR HRP20181622TT patent/HRP20181622T1/hr unknown
- 2018-10-22 CY CY20181101082T patent/CY1121021T1/el unknown
2019
- 2019-06-07 NO NO20190709A patent/NO344864B1/no unknown
2020
- 2020-06-23 US US16/909,686 patent/US11261191B2/en active Active
- 2020-08-25 IL IL276928A patent/IL276928B/en unknown
2021
- 2021-07-15 IL IL284889A patent/IL284889B2/en unknown
2022
- 2022-01-13 US US17/575,371 patent/US12084449B2/en active Active
- 2022-12-12 LU LU00293C patent/LUC00293I2/en unknown
- 2022-12-13 NO NO2022057C patent/NO2022057I1/no unknown
- 2022-12-14 HU HUS2200052C patent/HUS2200052I1/hu unknown
- 2022-12-15 FR FR22C1060C patent/FR22C1060I2/fr active Active
- 2022-12-16 CY CY2022037C patent/CY2022037I2/el unknown
- 2022-12-16 NL NL301209C patent/NL301209I2/nl unknown

Also Published As

Publication number	Publication date
KR20150014476A (ko)	2015-02-06
ES2398843T3 (es)	2013-03-22
CY2022037I2 (el)	2023-03-24
HK1225978B (zh)	2017-09-22
FR22C1060I1 (fr)	2023-02-03
CY1116763T1 (el)	2017-03-15
ME02372B (me)	2016-06-20
EA201691862A2 (ru)	2017-09-29
US20110136781A1 (en)	2011-06-09
SI3034075T1 (sl)	2018-12-31
RS57741B1 (sr)	2018-12-31
EA032254B1 (ru)	2019-04-30
KR101532256B1 (ko)	2015-06-29
NO2022057I1 (no)	2022-12-13
US11261191B2 (en)	2022-03-01
PL3034075T3 (pl)	2019-03-29
NL301209I1 (nl)	2022-12-21
HRP20160077T1 (hr)	2016-02-12
EA200970501A1 (ru)	2009-12-30
US20200317680A1 (en)	2020-10-08
PL2497470T3 (pl)	2016-04-29
AU2007323725B2 (en)	2014-02-20
MY188335A (en)	2021-11-30
EP2497470B1 (en)	2015-10-28
PT3034075T (pt)	2018-11-05
IL276928B (en)	2022-03-01
US20230002392A1 (en)	2023-01-05
GEP20125658B (en)	2012-10-10
BRPI0719333A2 (pt)	2014-02-04
RS54510B1 (en)	2016-06-30
PL2099447T3 (pl)	2013-06-28
CN101641093B (zh)	2013-05-29
IL198716A (en)	2016-03-31
LUC00293I2 (nl)	2024-10-04
HK1175700A1 (zh)	2013-07-12
IL284889B2 (en)	2023-05-01
PT2099447E (pt)	2013-02-27
US20130324515A1 (en)	2013-12-05
MY188338A (en)	2021-11-30
EP2099447A1 (en)	2009-09-16
NO344399B1 (no)	2019-11-25
PT2497470E (pt)	2016-02-22
LT3034075T (lt)	2018-11-26
AU2007323725A1 (en)	2008-05-29
NZ577127A (en)	2012-03-30
IL284889B1 (en)	2023-01-01
US10738052B2 (en)	2020-08-11
US7767675B2 (en)	2010-08-03
CR10841A (es)	2009-06-30
CY1121021T1 (el)	2020-05-29
CY1117108T1 (el)	2017-04-05
ES2560435T3 (es)	2016-02-19
EP3034075A1 (en)	2016-06-22
US8461330B2 (en)	2013-06-11
CY2022037I1 (el)	2023-01-27
IL284889A (en)	2021-08-31
TW200835481A (en)	2008-09-01
TWI429432B (zh)	2014-03-11
IL244244B (en)	2020-09-30
EP3443958A1 (en)	2019-02-20
CN103288833B (zh)	2018-01-12
HUE026659T2 (en)	2016-07-28
JP2010510319A (ja)	2010-04-02
NO344864B1 (no)	2020-06-02
NO20200077A1 (no)	2009-07-28
EA201691862A3 (ru)	2017-12-29
SI2099447T1 (sl)	2013-03-29
DK2497470T3 (en)	2015-12-07
EP2497470B8 (en)	2015-12-02
SI2497470T1 (sl)	2016-02-29
EA026126B1 (ru)	2017-03-31
EP2099447B1 (en)	2012-11-07
KR101588583B1 (ko)	2016-01-28
NO346024B1 (no)	2022-01-03
ES2689444T3 (es)	2018-11-14
HRP20181622T1 (hr)	2018-12-14
NO20091924L (no)	2009-07-28
WO2008064157A1 (en)	2008-05-29
IL198716A0 (en)	2010-02-17
MX2009005144A (es)	2009-05-27
US12084449B2 (en)	2024-09-10
HUS2200052I1 (hu)	2023-01-28
AR066142A1 (es)	2009-07-29
US20180282340A1 (en)	2018-10-04
US20080167287A1 (en)	2008-07-10
CN101641093A (zh)	2010-02-03
EP2497470A1 (en)	2012-09-12
ME01507B (me)	2014-04-20
FR22C1060I2 (fr)	2023-11-17
DK2099447T3 (da)	2013-02-18
DK3034075T3 (en)	2018-10-22
RS52677B (en)	2013-06-28
US9944645B2 (en)	2018-04-17
ECSP099400A (es)	2009-07-31
HK1136489A1 (en)	2010-07-02
HRP20130106T1 (hr)	2013-03-31
CA2669991C (en)	2016-01-26
EP3034075B1 (en)	2018-07-25
CO6210810A2 (es)	2010-10-20
CA2669991A1 (en)	2008-05-29
CL2007003341A1 (es)	2008-04-18
KR20090094299A (ko)	2009-09-04
JP5572388B2 (ja)	2014-08-13
NO20190709A1 (no)	2009-07-28
US20160326178A1 (en)	2016-11-10
CN103288833A (zh)	2013-09-11
IL244244A0 (en)	2016-04-21
IL276928A (en)	2020-10-29

Publication	Publication Date	Title
NL301209I1 (nl)	2022-12-21	capmatinib of een farmaceutisch aanvaardbaar zout daarvan
NL301003I2 (nl)	2019-10-29	Sotagliflozin of een farmaceutisch aanvaardbaar zout daarvan
NL300993I2 (nl)	2019-07-11	Apalutamide of een farmaceutisch aanvaardbaar zout daarvan
NL301106I2 (nl)	2021-08-03	Cenobamaat of een farmaceutisch aanvaardbaar zout daarvan
NL301305I2 (nl)	2024-12-30	Vibegron of een farmaceutisch aanvaardbaar zout daarvan
NL301166I2 (nl)	2022-07-06	Avacopan of een farmaceutisch aanvaardbaar zout daarvan
NL301256I2 (nl)	2024-01-11	cedazuridine, of een farmaceutisch aanvaardbaar zout daarvan
NL301071I2 (nl)	2020-12-01	alpelisib of een farmaceutisch aanvaardbaar zout ervan
NL301250I2 (nl)	2023-11-23	piflufolastat (18F) of een farmaceutisch aanvaardbaar zout daarvan
NL301304I2 (nl)	2024-12-19	aprocitentan of een farmaceutisch aanvaardbaar zout daarvan
NL301291I2 (nl)	2024-10-30	sparsentan of een farmaceutisch aanvaardbaar zout daarvan
NL301187I2 (nl)	2022-08-04	Rimegepant of een farmaceutisch aanvaardbaar zout daarvan
NL301035I2 (nl)	2020-04-15	upadacitinib of een farmaceutisch aanvaardbaar zout daarvan
NL350108I2 (nl)	2022-12-07	Isofetamid of een zout daarvan
NL301202I1 (nl)	2022-11-09	Linzagolix, of een farmaceutisch aanvaardbaar zout daarvan, zoals linzagolix choline
NO2019027I1 (no)	2019-07-04	kobicistat eller et farmasøytisk akseptabelt salt derav
NL300865I2 (nl)	2020-08-17	Eluxadoline of een farmaceutisch aanvaardbaar zout ervan
NL300886I2 (nl)	2017-10-24	baricitinib, of een farmaceutisch aanvaardbaar zout daarvan
NL301284I2 (nl)	2024-09-04	Etrasimod, of een farmaceutisch aanvaardbaar zout daarvan, zoals etrasimod arginine
FIC20240039I1 (fi)	2024-11-12	Kapivasertibi, valinnaisesti farmaseuttisesti hyväksyttävän suolan muodossa
FIC20190029I1 (fi)	2019-05-17	Brigatinibi tai sen farmaseuttisesti hyväksyttävä suola
NL301065I2 (nl)	2020-10-28	Ozanimod of een farmaceutisch aanvaardbaar zout daarvan, in het bijzonder ozanimodhydrochloride
NO2020038I1 (no)	2020-11-18	Ozanimod, or a pharmaceutically acceptable salt thereof, including the hydrochloride salt
NL301037I2 (nl)	2020-05-12	Solriamfetol of een farmaceutisch aanvaardbaar zout daarvan, bij voorkeur het hydrochloridezout daarvan
NO2017059I2 (no)	2017-11-13	ribosiklib eller et farmasøytisk akseptabelt salt derav